FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3201697832> ?p ?o ?g. }

• W3201697832 startingPage "199" @default.
• W3201697832 abstract "Background: The role of pidotimod in immune stimulation in conditions like asthma, chronic obstructive pulmonary disease, and recurrent respiratory tract infections is well established. This has led to its exploration in COVID-19, which is also characterized by immune dysregulation. We determined the efficacy and safety of pidotimod in paucisymptomatic SARS-CoV-2 patients.Methods: In this retrospective study, the electronic medical records (EMRs) of paucisymptomatic SARS-CoV-2 patients visiting the outpatient department at Kunal Institute of Medical Specialities Pvt Ltd, Bashir Bagh, Hyderabad, India between March 2021 and July 2021 were reviewed.  Patients having mild/moderate symptoms with PCR-documented SARS-CoV-2 positive from a nasopharyngeal sample were included in the study and divided into two groups (3:2): Group A (n=77) included patients who received pidotimod along with the standard of care treatment, and Group B (n=50) received only standard of care treatment for 14 days.  The effectiveness outcomes were the number of days taken for fever resolution, for relief of other symptoms, and negative swab test. Change in levels of various biomarkers involved in the pathogenesis of COVID-19 from baseline to 7days and 14days of treatment, was observed. Safety was assessed by adverse events reported during the treatment period.Results: Overall, 140 patients were included, of which 13 were excluded as they had signs of pneumonia or respiratory failure. The mean age of the patients was 32.88 ± 10.86 and 31.20 ± 11.81 years in Group A and Group B respectively. Co-morbidities such as diabetes (28.6% in Group A and 24% in Group B) and hypertension (32.5% in Group A and 28% in Group B) were observed in the patients. The majority of the patients presented with fever and cough. Patients in Group A showed an earlier fever resolution (3.58 ± 1.04 days vs 7.29 ± 3.12 days) as well as earlier resolution of other symptoms (4.16  days ± 1.03 days vs. 7.10 days ± 2.45 days), when compared to Group B, respectively. Similarly, the swab test of patients was reported negative earlier (10.56 days ± 3.11 days) in Group A vs. Group B (13.74 days ± 2.45 days). Furthermore, a significant decline (p<0.001) in elevated levels of various biomarkers like CRP (64.27% vs. 59.52%) and IL-6 (51.03% vs. 33.31%) was observed after 14 days in patients receiving pidotimod, when compared with control group. A noteworthy improvement in the levels of d-dimer (521.48 ng/ml ± 166.14 ng/ml to 377.74 ng/ml ± 102.59 ng/ml) was observed in the pidotimod group after 7 days of treatment than that in the control group (656.58  ng/ml ± 193.93 ng/ml to 529.74 ng/ml ± 156.47 ng/ml); with corresponding reductions of 27.56% and 19.31%, respectively. Similarly, a significant reduction (p<0.001) in the levels of ferritin was found in the pidotimod group (45.66%) as compared to the control group (30.39%). No serious adverse events were reported during the 14 days of treatment in both groups.Conclusion: Pidotimod, as an adjuvant therapy for the treatment of paucisymptomatic SARS-CoV-2 patients, was observed to decrease the levels of inflammatory mediators and other biological markers in patients. Pidotimod appears to have a potential role in managing SARS-CoV-2 patients." @default.
• W3201697832 created "2021-10-11" @default.
• W3201697832 creator A5057408318 @default.
• W3201697832 creator A5066708800 @default.
• W3201697832 creator A5070865506 @default.
• W3201697832 creator A5078562383 @default.
• W3201697832 date "2021-01-01" @default.
• W3201697832 modified "2023-09-23" @default.
• W3201697832 title "Efficacy and Safety of Pidotimod in SARS-CoV-2 Management: A Real-world Evidence Study" @default.
• W3201697832 hasPublicationYear "2021" @default.
• W3201697832 type Work @default.
• W3201697832 sameAs 3201697832 @default.
• W3201697832 citedByCount "0" @default.
• W3201697832 crossrefType "journal-article" @default.
• W3201697832 hasAuthorship W3201697832A5057408318 @default.
• W3201697832 hasAuthorship W3201697832A5066708800 @default.
• W3201697832 hasAuthorship W3201697832A5070865506 @default.
• W3201697832 hasAuthorship W3201697832A5078562383 @default.
• W3201697832 hasConcept C126322002 @default.
• W3201697832 hasConcept C187212893 @default.
• W3201697832 hasConcept C195910791 @default.
• W3201697832 hasConcept C197934379 @default.
• W3201697832 hasConcept C2777914695 @default.
• W3201697832 hasConcept C71924100 @default.
• W3201697832 hasConceptScore W3201697832C126322002 @default.
• W3201697832 hasConceptScore W3201697832C187212893 @default.
• W3201697832 hasConceptScore W3201697832C195910791 @default.
• W3201697832 hasConceptScore W3201697832C197934379 @default.
• W3201697832 hasConceptScore W3201697832C2777914695 @default.
• W3201697832 hasConceptScore W3201697832C71924100 @default.
• W3201697832 hasIssue "9" @default.
• W3201697832 hasLocation W32016978321 @default.
• W3201697832 hasOpenAccess W3201697832 @default.
• W3201697832 hasPrimaryLocation W32016978321 @default.
• W3201697832 hasRelatedWork W2354046760 @default.
• W3201697832 hasRelatedWork W2412426915 @default.
• W3201697832 hasRelatedWork W2418620840 @default.
• W3201697832 hasRelatedWork W2992858290 @default.
• W3201697832 hasRelatedWork W3009680977 @default.
• W3201697832 hasRelatedWork W3032028485 @default.
• W3201697832 hasRelatedWork W3040886970 @default.
• W3201697832 hasRelatedWork W3043764490 @default.
• W3201697832 hasRelatedWork W3045945391 @default.
• W3201697832 hasRelatedWork W3087596809 @default.
• W3201697832 hasRelatedWork W3107434441 @default.
• W3201697832 hasRelatedWork W3123314688 @default.
• W3201697832 hasRelatedWork W3126358415 @default.
• W3201697832 hasRelatedWork W3126691690 @default.
• W3201697832 hasRelatedWork W3131580109 @default.
• W3201697832 hasRelatedWork W3136874727 @default.
• W3201697832 hasRelatedWork W3139726388 @default.
• W3201697832 hasRelatedWork W3157033256 @default.
• W3201697832 hasRelatedWork W3195399570 @default.
• W3201697832 hasRelatedWork W3204345505 @default.
• W3201697832 hasVolume "15" @default.
• W3201697832 isParatext "false" @default.
• W3201697832 isRetracted "false" @default.
• W3201697832 magId "3201697832" @default.
• W3201697832 workType "article" @default.